Press releases and financial reports

In the CombiGenes pressroom you will find press releases, newsletters, and the latest reports. High resolution images as well as logos are available for use in articles and in newsstands.

Copyright applies to all footage.

CombiGene AB (publ): Nominating committee

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting (“AGM”) 2020 The AGM 2020 resolved that a nominating committee should be appointed...

read more

Interim Report January – September 2020

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 Interim Report January – September 2020 for CombiGene AB (publ)för CombiGene AB (publ) About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the...

read more

Updated analysis of CombiGene

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 Analysguiden has today updated its analysis of CombiGene. You can find the result here: 2021 » News » Regulatory news » Financial reports...

read more

Find it easy


"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99


Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook